bpc-157 arthritis clinical studies Data: Promising, But Not Proven In Humans, Early animal suggest BPC-157 may reduce pain behaviors in inflammatory and non-inflammatory models, including reduced allodynia. But this Capsule count:30 Capsules BPC-157 is marketed as knee pain

bpc-157 arthritis clinical studies Data: Promising, But Not Proven In Humans, Early animal suggest BPC-157 may reduce pain behaviors in inflammatory and non-inflammatory models, including reduced allodynia. But this Capsule count:30 Capsules BPC-157 is marketed as knee pain

BPC-157 is marketed as a “healing peptide” for tendon injuries, muscle strains, and joint pain—but the hype has moved much faster than the human evidence. Its story traces back to research involving

First-line pharmacologic options (evidence-based): Gabapentin/pregabalin , tricyclic antidepressants (e.g., amitriptyline/nortriptyline), and topical 5% lidocaine patches

knee pain

Capsule count:30 Capsules

Staquicini et al